[go: up one dir, main page]

MX2007006564A - Formulaciones de benzoxazoles sustituidos. - Google Patents

Formulaciones de benzoxazoles sustituidos.

Info

Publication number
MX2007006564A
MX2007006564A MX2007006564A MX2007006564A MX2007006564A MX 2007006564 A MX2007006564 A MX 2007006564A MX 2007006564 A MX2007006564 A MX 2007006564A MX 2007006564 A MX2007006564 A MX 2007006564A MX 2007006564 A MX2007006564 A MX 2007006564A
Authority
MX
Mexico
Prior art keywords
formulations
substituted benzoxazoles
manufacture
processes
benzoxazoles
Prior art date
Application number
MX2007006564A
Other languages
English (en)
Inventor
Mannching Sherry Ku
James A Provost
Trevor I Armstrong
Zerina B Shafi
Marc S Tesconi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007006564A publication Critical patent/MX2007006564A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a formulaciones solidas de dosificacion que incluyen ligandos selectivos de ER( que contienen benzoxazol, y a procedimientos para la fabricacion de dichas formulaciones, mas particularmente a formulaciones y procedimientos novedosos para la fabricacion de formulaciones que contienen el ligando selectivo de ER(, ERB-041.
MX2007006564A 2004-12-02 2005-11-30 Formulaciones de benzoxazoles sustituidos. MX2007006564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63237504P 2004-12-02 2004-12-02
PCT/US2005/043407 WO2006060532A2 (en) 2004-12-02 2005-11-30 Formulations of substituted benzoxazoles

Publications (1)

Publication Number Publication Date
MX2007006564A true MX2007006564A (es) 2007-06-19

Family

ID=36565706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006564A MX2007006564A (es) 2004-12-02 2005-11-30 Formulaciones de benzoxazoles sustituidos.

Country Status (22)

Country Link
US (1) US20060121110A1 (es)
EP (1) EP1850833A2 (es)
JP (1) JP2008521919A (es)
KR (1) KR20070089921A (es)
CN (1) CN101128188A (es)
AR (1) AR053653A1 (es)
AU (1) AU2005311823A1 (es)
BR (1) BRPI0518786A2 (es)
CA (1) CA2589033A1 (es)
CR (1) CR9144A (es)
GT (1) GT200500349A (es)
IL (1) IL183393A0 (es)
MX (1) MX2007006564A (es)
NI (1) NI200700139A (es)
NO (1) NO20072636L (es)
NZ (1) NZ555395A (es)
PE (1) PE20061083A1 (es)
RU (1) RU2007120253A (es)
SV (1) SV2006002317A (es)
TW (1) TW200626144A (es)
WO (1) WO2006060532A2 (es)
ZA (1) ZA200705011B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137626A (zh) * 2005-03-08 2008-03-05 惠氏公司 2－(3－氟－4－羟基苯基)－7－乙烯基－1,3－苯并唑－5－醇的晶形及其作为雌激素受体调节剂的用途
BRPI0707655A2 (pt) * 2006-02-14 2011-05-10 Wyeth Corp composiÇço farmacÊutica aquosa, mÉtodo para preparar uma composiÇço farmacÊutica, produto, mÉtodo para tratar um indivÍduo sofrendo de artrite ou endometriose, e, kit
TW200800178A (en) * 2006-03-06 2008-01-01 Wyeth Corp Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
TW200803850A (en) * 2006-03-06 2008-01-16 Wyeth Corp Tablet formulations and processes
TW200800179A (en) * 2006-03-06 2008-01-01 Wyeth Corp Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
TW200800180A (en) * 2006-03-06 2008-01-01 Wyeth Corp Liquid and semi-solid pharmaceutical formulations and processes
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7045539B2 (en) * 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
EP1499391A2 (en) * 2002-04-10 2005-01-26 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant

Also Published As

Publication number Publication date
PE20061083A1 (es) 2006-11-14
NO20072636L (no) 2007-08-13
KR20070089921A (ko) 2007-09-04
AU2005311823A1 (en) 2006-06-08
GT200500349A (es) 2006-07-03
CR9144A (es) 2007-11-23
WO2006060532A3 (en) 2006-11-16
EP1850833A2 (en) 2007-11-07
AR053653A1 (es) 2007-05-16
SV2006002317A (es) 2006-06-26
ZA200705011B (en) 2010-01-27
WO2006060532A2 (en) 2006-06-08
NZ555395A (en) 2009-07-31
RU2007120253A (ru) 2009-01-10
NI200700139A (es) 2008-05-09
TW200626144A (en) 2006-08-01
US20060121110A1 (en) 2006-06-08
JP2008521919A (ja) 2008-06-26
CN101128188A (zh) 2008-02-20
CA2589033A1 (en) 2006-06-08
IL183393A0 (en) 2007-09-20
BRPI0518786A2 (pt) 2008-12-09

Similar Documents

Publication Publication Date Title
NI200700139A (es) Formulaciones de benzoxazoles sustituidos
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
SI1888541T1 (sl) Benzo(d)izoksazol-3-il-aminske spojine in njihova uporaba kot ligandi vaniloidnega receptorja
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
MA31245B1 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
TW200800967A (en) Benzimidazole thiophene compounds
MX2009010047A (es) Compuestos quimicos.
EP1633740A4 (en) CHEMICAL COMPOUNDS
MX2009010045A (es) Compuestos quimicos.
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
TW200626068A (en) Active compounds for seed treatment
MX2007007588A (es) Analogos de tetrahidroquinolina como agonistas muscarinicos.
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
TW200510317A (en) Caspase inhibitors and uses thereof
SE0401762D0 (sv) Novel compounds
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
GB0402809D0 (en) Chemical compounds
TW200738659A (en) Novel compounds
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
MA31445B1 (fr) Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
MX2007006565A (es) Formulaciones de benzoxazoles sustituidos.
PL1758852T3 (pl) Podstawione związki cyklopentenu
TW200700071A (en) Novel use
TW200745039A (en) Isotopically substituted pantoprazole
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych